• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Switzerland·Healthcare·AEVS.SW
Share

Aevis Victoria SA Stocks

CHF 15.1Last Updated 05.10.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

CHF 1.54B

CHF 15.1
Key Takeaways

Risk factor

Strong & resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Aevis Victoria SA is a Swiss holding company with diversified interests spanning the healthcare, hospitality, lifestyle, and infrastructure sectors. Its operational structure is divided into key segments: Hospitals, Hospitality, Telemedicine, and Real Estate. The group manages an extensive portfolio, which includes 22 hospitals providing 1,496 beds, and oversees 941 rooms within its real estate holdings, representing a total rentable area of 188,109 square meters. Beyond its core hospital services, Aevis Victoria offers telemedicine, ambulance transport, and day clinic facilities. Its broad range of business ventures further encompasses patient hotels, "better aging" programs, radiology institutes, pharmacies, ophthalmology clinics, property management, stem cell applications, cosmetic services, and publishing, alongside organizing various seminars. The company's corporate headquarters are situated in Fribourg, Switzerland, and it operates as a subsidiary of M.R.S.I. Medical Research, Services and Investments S.A.

Company Valuation

Overvalued
2/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBIT

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Slightly negative
3/7

The average target price of AEVS.SW is 17.0 and suggests 12.6% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommenda

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.10.2026 03:00

BofA Identified Three Risks for Apple if SpaceX Becomes a Mobile Carrier

13.10.2026 02:01

Meta launches Muse Wonder AI model, says it has caught up with industry leaders

13.10.2026 01:16

Microsoft could deploy over a million of its own AI chips in 2027, challenging Nvidia

13.10.2026 00:39

Walmart is outperforming luxury stocks. Is that sign of a coming Fed rate cut?

12.10.2026 23:19

LVMH fashion and leather sales disappoint in 3Q due to demand slowdown in China

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026